Skip to main content
Erschienen in: Hernia 3/2020

Open Access 20.02.2020 | Original Article

Long-term outcomes after contaminated complex abdominal wall reconstruction

verfasst von: F. E. E. de Vries, J. D. Hodgkinson, J. J. M. Claessen, O. van Ruler, C. A. Leo, Y. Maeda, O. Lapid, M. C. Obdeijn, P. J. Tanis, W. A. Bemelman, J. Constantinides, G. B. Hanna, J. Warusavitarne, C. Vaizey, M. A. Boermeester

Erschienen in: Hernia | Ausgabe 3/2020

Abstract

Purpose

Complex abdominal wall repair (CAWR) in a contaminated operative field is a challenge. Available literature regarding long-term outcomes of CAWR comprises studies that often have small numbers and heterogeneous patient populations. This study aims to assess long-term outcomes of modified-ventral hernia working group (VHWG) grade 3 repairs. Because the relevance of hernia recurrence (HR) as the primary outcome for this patient group is contentious, the need for further hernia surgery (FHS) was also assessed in relation to long-term survival.

Methods

A retrospective cohort study with a single prospective follow-up time-point nested in a consecutive series of patients undergoing CAWR in two European national intestinal failure centers.

Results

In long-term analysis, 266 modified VHWG grade 3 procedures were included. The overall HR rate was 32.3%. The HR rates for non-crosslinked biologic meshes and synthetic meshes when fascial closure was achieved were 20.3% and 30.6%, respectively. The rates of FHS were 7.2% and 16.7%, and occurred only within the first 3 years. Bridged repairs showed poorer results (fascial closure 22.9% hernia recurrence vs bridged 57.1% recurrence). Overall survival was relatively good with 80% en 70% of the patients still alive after 5 and 10 years, respectively. In total 86.6% of the patients remained free of FHS.

Conclusions

In this study of contaminated CAWR, non-crosslinked biologic mesh shows better results than synthetic mesh. Bridging repairs with no posterior and/or anterior fascial closure have a higher recurrence rate. The overall survival was good and the majority of patients remained free of additional hernia surgery.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Complex abdominal wall repair (CAWR) in a potentially contaminated operative field is a challenge. Sources of contamination such as the presence of a stoma, concomitant bowel surgery, enterocutaneous fistulas (ECF) or infected mesh increase the risk of wound complications [1, 2]. Additionally, patients may have coexisting intestinal failure, possibly worsening postoperative morbidity [36].
Available literature regarding outcomes of contaminated ventral hernia repair is sparse and often studies have small numbers and heterogeneous patient populations [7, 8]. Moreover, there is no standardization of outcome reporting. The choice of mesh remains controversial; synthetic and biologic crosslinked meshes are feared due to the risk of infection and fistulation while non-crosslinked biologic meshes are expensive, and long-term durability remains questionable [9, 10]. Because of these factors, a randomized controlled trial in this complex group of patients seems unachievable.
A recent systematic review [7] found 601 contaminated procedures described in 16 studies with an overall recurrence rate of 24.3% after an average follow-up period of 26.7 months. Hernia rates varied between studies, with huge heterogeneity in patients, mesh use and mesh positioning. Bridging repairs had a higher recurrence rate (40.0%) compared to repairs in which fascial closure was achieved (16.0%). Another systematic review, also including potentially contaminated procedures, found a weighted pooled recurrence rate of 9% for potentially contaminated procedures and 30% for contaminated procedures [8].
In contrast to clean or small hernias, this group of patients undergo months of complex wound and stoma care, and sometimes require home parenteral nutrition (PN). Therefore, the relevance of a recurrent hernia as an outcome measure, if small and asymptomatic, could be questioned.
In 2012, Kanters et al. [2] proposed the modified Ventral Hernia Working Group (VHWG) classification, replacing the original 2010 VHWG classification [1]. In this new classification, grade 3 and 4 hernias with (potential) contamination were combined to a modified VHWG grade 3. Patients with a previous wound infection, but no contamination at the time of surgery, were removed from the modified VHWG grade 3 group. A number of studies have assessed risk factors for hernia recurrence in this cohort. Factors such as active smoking, increased BMI, number of previous hernia repairs, number of previous abdominal surgeries and the use of bridging mesh were found to be significantly associated with hernia recurrence [11, 12].
This study aimed to assess long-term outcomes of modified VHWG grade 3 repairs in a combined cohort from a UK and a Dutch national referral center for intestinal failure. As the relevance of clinical hernia recurrence as the primary outcome for this complex and specific patient group is contentious, the need for further hernia surgery was also assessed in relation to overall survival.

Material and methods

Study design and data collection

This was a retrospective cohort study with a single prospective follow-up time-point nested in a consecutive series of patients undergoing CAWR in two European centers with nationwide referral for intestinal failure. All patients with modified VHWG grade 3 defects (clean-contaminated, contaminated or dirty) [2], operated in either the Amsterdam University Medical Centres (AUMC), location AMC, Amsterdam, the Netherlands or St Marks Hospital (SMH), London, United Kingdom, between 2004 and 2015 were identified. The VHWG grade 3 group involves patients with a stoma, concomitant bowel surgery, enterocutaneous fistulas (ECF) or infected mesh. The study protocol was approved by the medical ethical committees of both hospitals. All patients signed informed consent prior to participation and data were stored in a secured database.
Baseline characteristics on patient demographics, surgical procedures, and postoperative follow-up were collected by retrospective case note review. All patients still alive were invited to participate in a single out-patient clinic visit. If patients were not able to visit, they were requested to answer a questionnaire regarding long-term follow-up by telephone. If patients did not respond within 4 weeks, a second invitation to participate was sent. For patients who were not reachable or unable to attend, their last confirmed abdominal examination performed at the out-patient clinic was used as their last abdominal follow-up. The following definitions were used: overall survival (last moment the patient was known to be alive), hernia free survival (either the last moment a physician performed an abdominal examination without finding a recurrent hernia or the last known abdominal imaging without a hernia) and hernia-related-surgery free survival (last day before the patient underwent new hernia repair). If a patient had a midline laparotomy for another indication then hernia repair, patients were censored on the day of surgery.

Outcome and definitions

The operative reconstruction was categorized by primary suture repair, synthetic mesh or non-crosslinked biologic mesh. For biologic mesh, these were further classified into biologic only, biologic in combination with synthetic absorbable mesh (SAM), and biologic in combination with synthetic non-absorbable mesh (SNAM). For synthetic mesh, these were further classified as SAM, SNAM and a combination of SAM and SNAM. Primary outcome was overall hernia recurrence. Hernia recurrence was further classified as clinically symptomatic (either needing surgery or reported as symptomatic by the patient) or asymptomatic. Additional surgery for hernia recurrence (interventional outcome) was classified as surgery for a recurrent clean hernia or for a recurrent (potentially) contaminated hernia. The results were stratified by fascial closure achieved repairs and bridged repairs. Intestinal failure (IF) is defined as the inability of the intestinal tract to maintain protein/energy, fluid, electrolyte or micronutrient balance resulting in the need for intravenous (iv) fluid supplementation and/or total parenteral nutrition (TPN) [13]. The ability to wean off PN within 2 years after reconstructive surgery was also recorded, as recommended by the European Society of Coloproctology (ESCP) intestinal failure guidelines [13]. Patients visiting the out-patient clinic were asked to perform the Trunk-raising test [14] to test their abdominal muscle strength (straight sit-up on a 5-point scale, “Appendix”).

Surgical technique

Both centers have a long-standing history of treating patients with contaminated abdominal wall defects and intestinal failure, and operative strategies were comparable between the centers and consistent with published guidelines and consensus [13].
Peri-operative infection prevention measures were used according to local standards and included appropriate antibiotic prophylaxis administration before incision, hand-hygiene, and surgical site preparation with an alcohol and chlorhexidine based anti-septic agent. At the AUMC, closed incision negative pressure wound therapy was introduced in January 2014. Both centers had a preference for planned admission to a high dependency unit for at least 24 h postoperatively.
Operative goals were driven by best practice evidence at the time of surgery. Briefly, according to consensus on the management of patients with intestinal failure; enterocutaneous fistulas were resected and, usually, a primary hand sewn anastomosis was performed; number of anastomoses was minimized; a double layer anastomosis was preferred; and up-stream diverting stomas were used whenever necessary. The primary aim of repair of the abdominal wall defect was tension-free fascial closure with reinforcing mesh where possible. Component separation techniques (CST) were used if required and possible. Plastic and reconstructive surgeons were consulted and performed reconstruction in cases of large full thickness skin defects and those with significant loss of domain.
Choice of mesh type was tailored to the individual patient but based on some basic principles. In defects with minimal contamination (for example stoma present) and a defect that could be closed after CST, a SNAM could be used. If there was gross contamination, biologic, SAM or no mesh was preferred. Up until 2011, SAM (polyglactin) was preferred in both centers, after this, a non-crosslinked biological mesh became the primary choice, preferably in an intra-abdominal (IPOM) or retro-rectus (sublay) position. In some cases, with particularly large defects, a double or even triple layer mesh technique was employed based on surgeon choice.
Fascial closure was typically performed using a looped monofilament polydioxanone (PDS) suture. If fascial closure was not achievable, the defect was bridged using an intra-abdominal or retro-muscular mesh or both. Passive intra-abdominal drains were used where deemed appropriate but not routinely, and active subcutaneous drains were used routinely. Drains were removed when output was below 30 ml/24 h. No skin grafts were used to achieve primary skin closure. AUMC preferred interrupted polyester Mersilene sutures (Ethicon), whereas SMH tended to use surgical clips or interrupted polypropylene prolene sutures (Ethicon). If a plastic surgeon was involved layered closure was performed with absorbable sutures subcutaneous.
It was noted that post-operative wound infections/collections were managed differently between the two centers. AUMC had a preference for performing radiological percutaneous drainage of wound collections, whereas SMH routinely opened wounds at the bedside to drain collections.

Statistical analysis

Baseline characteristics are presented as numbers and percentages. Normally distributed data is presented as a mean with standard deviation (SD), while non-normally distributed data is presented as a median with interquartile range (IQR) or total range. Overall survival, hernia free survival, and hernia-related-surgery free survival were assessed using Kaplan Meier statistics and compared using a Log-rank test. Binary logistic regression was performed to identify risk factors associated with long-term complications. A p value of < 0.05 was considered significant.

Results

A total of 272 VHWG grade 3 contaminated abdominal wall reconstructions performed between 2004 and 2015 in 254 patients were included in the study. Mean age was 58.0 (SD 13.6) and 58.8% were male. Patient and operative characteristics are presented in Table 1. Six of the initial 254 patients (2.4%) died in-hospital and were therefore excluded from long-term assessment of hernia recurrence and re-repair, leaving 266 procedures in 248 patients.
Table 1
Patient and operative characteristics of 272 modified VHWG grade 3 procedures in 254 patients
 
272 procedures in 254 patients
Percentage of cohort (N)
Patient characteristics
 Age, mean (SD)
58.0 (SD 13.6)
 Sex male
58.8% (160)
 BMI
Median 26.0 (IQR 22.6–29.6)
 ASA classification, mean (SD)
Mean 2.43 (SD 0.5)
  2
59.6% (162)
  3
37.9% (103)
  4
2.6% (7)
 Active smoker
22.8 (62)
 Diabetes
18.4 (50)
 Immunosuppression
7.7 (21)
 Cardiac comorbidity,
23.2 (63)
 Pulmonary comorbidity
20.2 (55)
 COPD
10.7 (29)
 Hypertension
30.5 (83)
 IBD
14.3 (39)
 Intestinal failure
47.1 (129)
 Previous abdominal malignancy
18.4 (50)
 History of open abdomen
47.1 (128)
 Presence of intestinal fistula
58.1 (159)
Operative characteristics
 Number of previous abdominal surgeries, median
4 (IQR 2–5) (range 1–25)
 Undergone previous hernia repairs
43.8 (119)
 Time since last surgery
Median 349 days (IQR 240–636)
 CDC wound classification
  2
30.1 (82)
  3
45.6 (124)
  4
24.3 (66)
 Anastomosis constructed
73.5 (200)
 Mesh removal
21.7 (59)
 Component separation technique performed
 
  Yes
67.3 (183)
  No
31.6 (86)
  Unknown
1.1 (3)
 Mesh used
66.9 (182)
 Fascial closure
  Yes, fascial closure without mesh
32.4% (88)
  Yes, reinforcement with mesh
40.1% (109)
  No, bridging with mesh
24.6% (67)
  Unclear
2.9% (8)
BMI body mass index, ASA American Society of Anesthesiologists, COPD chronic obstructive pulmonary disease, IBD inflammatory bowel disease, CDC center for disease control and prevention

Survival

One-year mortality was 8.7% (22 patients including the in-hospital deaths (6)). After a mean follow-up of 36 months (range 0–153 months), another 21 patients died. Therefore, 211 of 254 patients (83.1%), who underwent a total of 229 procedures, were still alive at the time the study was performed. Actuarial 5-year and 10-year overall survival probabilities were 80% and 70%, respectively (Fig. 1).

Long-term follow-up

211 patients were invited to participate in a long-term follow-up out-patient clinic. We had a response rate of 71.1% (150 patients), and only 9 of those patients were unwilling to participate. Between October 2016 and March 2017, 99 patients were seen at the out-patient clinic, and 42 patients answered a questionnaire by telephone contact. For the remaining patients, we used the last available information from the medical records.

Use of mesh and mesh mediated risk factors

The choice of reconstruction technique was made by the attending surgeon based on the principles as described in our surgical technique section. Table 2 demonstrates the operative challenges and the corresponding choice of mesh. As shown in Table 2, SNAM were mostly used in procedures with low risk of contamination, while SAM (until 2011) and non-crosslinked biologic mesh (available from 2011 in both hospitals) were mostly used in procedures with high risk of contamination.
Table 2
A comparison of operative challenges and choice of mesh (n = 272) in all cases
 
ECF with infected mesh
ECF without infected mesh
Infected mesh
Violation of the GI-tracta
Stoma present
Other
Total (%)
No mesh
13
38
5
34
0
0
90 (33.1)
Biologicb
22
44
9
21
1
1
98 (36.0)
Biologic + SAMc
2
3
0
1
0
0
6 (2.2)
Biologic + SNAMd
0
1
1
2
1
1
6 (2.2)
SNAMe
1
2
1
5
10
3
22 (8.1)
SAMf
2
25
2
5
0
1
35 (12.9)
SNAM + SAMg
1
4
0
7
1
2
15 (5.5)
Total (%)
41 (15.0)
117 (43.0)
18 (6.6)
75 (27.6)
13 (4.8)
8 (2.9)
272 (100)
ECF enterocutaneous fistula, GI gastrointestinal, SAM synthetic absorbable mesh, SNAM synthetic non-absorbable mesh
afor example bowel resection, enterostomy creation or anastomosis
bMesh used: Strattice
cMesh used: Strattice, vicryl
dMesh used: Strattice, Vypro
eMesh used: Vypro, Ultrpro, Physiomesh, Surgisis, Proceed, Dualmesh, Prolene
fMesh used: Vicryl
gMesh used: Vypro, Vicryl
Mesh use, mesh type, and mesh position were further evaluated (Table 3). SAM or SNAM use was associated with an increased risk of recurrence and further surgery compared to biologic mesh. Bridging mesh was found to have a higher risk of symptomatic hernia recurrence compared to no mesh or the use of mesh as reinforcement [OR 4.22 (95% CI 1.53–11.60), p ≤ 0.01)]. The use of an additional mesh in high-risk patients was associated with an increased risk of hernia recurrence [OR 2.24 (95% CI 1.06–4.70), p = 0.03]. Surgery for hernia recurrence was more likely when a mesh was used in an onlay or bridging position (8.0% after fascial vs 25.7% after bridged closure).
Table 3
Mesh associated risk factors for hernia recurrence and further hernia surgery
 
Hernia recurrence
Further hernia surgery
OR (95%CI)
p value
OR (95%CI)
p value
Mesh type
 Biologic
1.27 (0.66–2.46)
0.48
2.40 (0.82–7.02)
0.11
 SNAM
2.30 (0.95–5.57)
0.07
6.11 (1.82–20.53)
< 0.01
 SAM
5.28 (2.40–11.61)
< 0.01
4.45 (1.39–14.24)
0.01
Mesh position
 Sublay IA
1.90 (0.99–3.65)
0.06
2.98 (1.03–8.65)
0.05
 Retrorectus
1.97 (0.72–5.37)
0.18
2.65 (0.58–12.07)
0.21
 Onlay
1.79 (0.79–4.04)
0.16
4.07 (1.24–13.36)
0.02
 Bridging IA sublay
4.22 (1.53–11.60)
< 0.01
5.60 (1.44–21.73)
0.01
Additional mesh
2.24 (1.06–4.70)
0.03
1.55 (0.62–3.83)
0.35
IA intra-abdominal, SAM synthetic absorbable mesh, SNAM synthetic non-absorbable mesh

Enterocutaneous fistula

Twenty patients developed an ECF postoperatively (7.5%). These were 18 recurrent and 2 new fistulas. Twelve patients had additional surgery for their (recurrent) fistula, and seven developed a long-term stable low-output fistula. One patient had spontaneous closure of the fistula after long-term conservative management.

Hernia recurrence and additional surgery for hernia recurrence

A total of 86 of the 266 (32.3%) procedures resulted in a recurrent hernia during follow-up. Thirty-six of these, 86 recurrences (13.5% of the total procedures and 41.9% of the recurrences) underwent additional hernia surgery. Table 4 shows hernia recurrence rates and surgery for hernia recurrence rates for both repairs with fascial closure and bridging repairs, and for different types of mesh. The hernia recurrence rates were 22.9% and 57.1% for fascial closure and bridging repair, while the rate of further hernia surgery were 8.0% and 25.7%, respectively. In selected cases with primary suture repair, 21.7% had a hernia recurrence and 4.8% underwent further hernia surgery. Biologic mesh showed fewer HR and further hernia surgery, both in bridged and facial closure repairs. Bridged repairs demonstrated poorer results, with a 45.7% recurrence rate for biologic mesh and 75.0% for synthetic mesh. Of these, 25.7% of the biologic mesh group underwent further hernia surgery compared to 28.1% in the synthetic mesh group. Figure 2 shows Kaplan Meier curves of hernia-free survival and hernia-related-surgery free survival, respectively. Log-rank tests showed a significant difference for both hernia recurrence and further hernia-related-surgery (p < 0.001) when comparing fascial closure with a bridged repair. Kaplan Meier regression showed that in patients where fascial closure was achieved, 86.6% were free from further surgery at 3 and 10 years.
Table 4
Long-term follow-up data demonstrating overall hernia recurrence and further hernia related surgery and divided by repair technique (no mesh, biologic mesh, synthetic mesh) and by ability to achieve fascial closure
 
Hernia recurrence
Additional surgery related to hernia recurrence
No bridging
Bridging
Unknown
No bridging
Bridging
Unknown
No mesh
18/83 = 21.7%
0/3
2/3
4/83 = 4.8%
0/3 
2/3
Biologic total
14/69 = 20.3%
16/35 = 45.7%
0/2
5/69 = 7.2%
9/35 = 25.7%
0/2
 Biologic onlya
13/63 = 20.6%
10/29 = 34.5%
0/2
5/63 = 7.9%
6/29 = 20.7%
0/2
 Biologic + SAMb
1/4
2/2
0/4
0/2
 Biologic + SNAMc
0/2
4/4
0/2
3/4
Synthetic total
11/36 = 30.6%
24/32 = 75%
1/3
6/36 = 16.7%
9/32 = 28.1%
1/3
 SNAMd
5/16 = 31.3%
4/5
0/1
3/16 = 18.8%
2/5
0/1
 SAMe
5/17 = 29.4%
15/17 = 88.2%
3/17 = 17.6%
4/17 = 23.5%
 SNAM + SAMf
1/3
5/10 = 50.0%
1/2
0/3
3/10 = 30.0%
1/2
Total
43/188 = 22.9%
40/70 = 57.1%
3/8
15/188 = 8.0%
18/70 = 25.7%
3/8
SAM synthetic absorbable mesh, SNAM synthetic non-absorbable mesh
aMesh used: Strattice
bMesh used: Strattice, vicryl
cMesh used: Strattice, Vypro
dMesh used: Vypro, Ultrpro, Physiomesh, Surgisis, Proceed, Dualmesh, Prolene
eMesh used: Vicryl
fMesh used: Vypro, Vicryl

Discontinuation of parenteral nutrition

At the time of reconstructive surgery, 125 patients (47.1%) of the present cohort depended on PN. We found that 104 patients (80.6%) successfully weaned of PN after a median of 54 days (range 1–562 days). Three patients died before they were able to wean PN. Therefore, 16 patients were still dependent on PN 2 years after surgery. Of those, six patients had an absolute short-bowel, four patients had a recurrent fistula, two patients had an atonic bowel segment and were therefore unable to discontinue PN, two patients remained on intravenous fluid supplementation only, one developed metastatic lung cancer, and one patient was unfit for reversal of a high stoma.

Trunk-raising test

All patients visiting the out-patient clinic were asked to perform the Trunk-Raising test [14]. Seventy patients performed the test and their median score was 5 (IQR 3–5) which is the maximum score on the test.

Discussion

Present study shows that, although overall hernia recurrence rates after contaminated CAWR are high, the majority of patients do not need to undergo further surgery, with an 80% 5-year overall survival rate. The overall hernia recurrence rate of 32.3% is comparable with literature [15], and results were worse in bridged repairs compared to repairs in which fascial closure could be achieved. Synthetic mesh use was associated with higher recurrence rates, although the operative challenge in these cases seems to have been less as shown by the level of contamination. When fascial closure was achieved, further hernia surgery was performed in the first 3 years and 86.6% of the patients never underwent further hernia surgery.
Previous studies [1620] showed worse results for bridged repairs compared to fascial closure achieved repairs. Our data are in line with literature and also reveals poor results for both hernia recurrence and for additional surgery when a bridged repair was used, with a quarter of the patients with recurrence undergoing further hernia surgery during follow-up (Fig. 2). Therefore, every effort should be made to achieve fascial closure.
Although the results of primary suture repair in this cohort are comparable to the use of biologic mesh, this is probably due to selection of less complex defects in which tension-free fascial closure could be achieved and a mesh not considered of additional value by the operating surgeon. This is supported by risk factor analysis, demonstrating that mesh was associated with recurrence, implying that mesh is more likely to be used in high risk cases. A previous study [17] has shown that primary suture repair or CST without mesh reinforcement have high recurrence rates. Therefore a reasonable indication for biologic mesh could be to allow fascial closure under tension and better distribution of forces in the midline, thereby achieving fascial closure even if it was deemed impossible prior to the application of biologic mesh.
Evaluation of mesh type and position revealed an apparent advantage of biologic mesh in long-term outcomes in comparison with synthetic meshes. Controversy exists regarding the choice of mesh in a contaminated setting. A recent systematic review and meta-analysis [8] including 32 studies showed comparable results for synthetic and biologic meshes in terms of hernia recurrence for potentially contaminated repairs, but higher recurrence rates were seen in contaminated repairs using biologic mesh. A more recent paper questions the use of biologic mesh altogether if compared to synthetic mesh, but highlighting the very low level of evidence in the field of CAWR [21]. Our data clearly show that there is an inevitable bias in comparing synthetic and biologic mesh. As shown in Table 2, most non-absorbable meshes were used in procedures with a relatively small risk of contamination (such as a stoma present), whereas most non-crosslinked biologic meshes were used for ECF or infected mesh surgery. Despite this selection bias, our data show better results for biologic mesh, both in hernia recurrence rates and re-repair rates. In other words, use of non-crosslinked biologic meshes could be beneficial in complex situations. A possible explanation for the higher incisional hernia recurrence rates for synthetic mesh might be that more synthetic non-absorbable mesh needed to be removed due to infectious complications.
Biologic mesh is currently recommended in guidelines [1, 13] for contaminated repairs, but costs are high and, therefore, the use of biologic mesh has sometimes been questioned. Long-term gains outweigh the initial high cost, considering that the overall survival in this group is good and the majority of patients do not undergo any further surgery and are subsequently weaned of PN. In this series, only non-crosslinked biologic mesh were used as several studies show poor results with cross-linked biologic mesh with high numbers of surgical site occurrence, mesh removal and fistulation [9, 10, 2123]. However, appropriate patient selection for the use of a non-crosslinked biologic mesh is of utmost importance, and studies to assess cost-effectiveness are needed.
Present study has several limitations. Most of the data was retrospectively collected and not all patients were available for long-term follow-up. However, as much information as possible was gathered by clinical examination, questionnaires and telephone interviews. Radiologic confirmation of a recurrent hernia was not achieved for all cases as we did not routinely perform CT follow-up; we only used available CTs in this study. A recent study demonstrates that incisional hernia cannot be diagnosed by patient-reported diagnostic questionnaire but might be used to rule out incisional hernia [24]. In addition, in this study, we faced the problem that the population of patients undergoing contaminated CAWR is heterogeneous and sometimes combination of meshes were used for the repair. Exclusion of the patients with combinations of meshes would not reflect daily practice, while choosing to make more groups results in very fragmented and small groups making it difficult to draw any conclusions. Therefore, we chose to include these patients and show the type of meshes used in the tables (Tables 2, 4). Other limitations included the fact that the cause of death after hospital discharge in most patients was unknown. This is because many patients were referred from external centers and, therefore, this data was impossible to obtain without informed consent. Although unlikely, it remains unknown whether long-term mortality is related to the CAWR. In assessing hernia-related-surgery free survival there is a bias, as patients deemed inoperable are not taken into account.
Despite these limitations, this is a large cohort of modified VHWG grade 3 procedures managed by the same treatment principles from two dedicated complex AWR and intestinal failure centers. The data suggest that bridged repairs should be avoided if possible and that non-crosslinked biologic mesh shows better results than synthetic mesh in contaminated CAWR.
As 80% of patients are still alive at 5-year follow-up and 86.6% of the patients remained free of additional surgery, the initial higher costs of a non-crosslinked biologic mesh seem trivial.

Compliance with ethical standards

Conflict of interest

JDH, FEEdV, JJMC, CAL, YM, OvR, OL, MCO, PJT, WAB, JC, GBH and JW declare no conflict of interest directly related to the current work; CJV declares no conflict of interest directly related to the current work and declares consultancy advisor to Acelity and paid lecture for Allergan. MAB declares no conflict of interest directly related to the current work and reports institutional research grants from Baxter, Mylan, Ipsen, Acelity/KCI, Bard, LifeCell and Johnson & Johnson/Ethicon and New Compliance; and is a speaker or advisory board member for Acelity/KCI, Bard, LifeCell/Allergan, Gore, Bard, Smith&Nephew and Johnson & Johnson/Ethicon.

Ethical approval

The study protocol was approved by the medical ethical committees of both hospitals.

Human and animal rights

Most of the study is retrospective data collected in a hernia database. Patients had one prospective follow-up moment and had to fill a questionnaire. These procedures were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments.
All patients signed informed consent prior to participation and data were stored in a secured database.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

Die Chirurgie

Print-Titel

Das Abo mit mehr Tiefe

Mit der Zeitschrift Die Chirurgie erhalten Sie zusätzlich Online-Zugriff auf weitere 43 chirurgische Fachzeitschriften, CME-Fortbildungen, Webinare, Vorbereitungskursen zur Facharztprüfung und die digitale Enzyklopädie e.Medpedia.

Bis 30. April 2024 bestellen und im ersten Jahr nur 199 € zahlen!

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Anhänge

Appendix: Trunk-raising test

The patient lies in a supine position with the hips flexed at 45° and the knees at 90°. The examiner asks the patient to perform a curl-up by raising both the head and the shoulder blades from the table and holding this position for a minimum of 20 s. The score for this test is determined by the arm position the patient uses to elevate the scapulae off the table while the time the patient is able to hold this position is measured.
For a maximum score, the hands are to be clasped behind the head, and the position needs to be maintained for 20 s. If this is not feasible for the patient, the second option is to cross the arms in front of the body. The third option is to have both arms reaching out in front of the body. The potential scores are as follows:
  • Hands behind neck, scapulae clearing the table, 20-s hold (normal) (5 points).
  • Arms crossed over chest, scapulae clearing the table, 20-s hold (good) (4 points).
  • Arms straight, scapulae clearing the table, 10-s hold (fair) (3 points).
  • Arms extended toward knees, top of scapulae lifting from the table (poor) (2 points).
  • Inability to raise more than head off the table (trace) (1 point).
Literatur
1.
Zurück zum Zitat Ventral Hernia Working Group, Breuing K, Butler CE et al (2010) Incisional ventral hernias: review of the literature and recommendations regarding the grading and technique of repair. Surgery 148(3):544–558CrossRef Ventral Hernia Working Group, Breuing K, Butler CE et al (2010) Incisional ventral hernias: review of the literature and recommendations regarding the grading and technique of repair. Surgery 148(3):544–558CrossRef
2.
Zurück zum Zitat Kanters AE, Krpata DM, Blatnik JA et al (2012) Modified hernia grading scale to stratify surgical site occurrence after open ventral hernia repairs. J Am Coll Surg 215(6):787–793CrossRef Kanters AE, Krpata DM, Blatnik JA et al (2012) Modified hernia grading scale to stratify surgical site occurrence after open ventral hernia repairs. J Am Coll Surg 215(6):787–793CrossRef
3.
Zurück zum Zitat Engledow A, Chan S, Forbes A et al (2010) The management of enterocutaneous fistula in a regional unit in the United kingdom: a prospective study. Dis Colon Rectum 53(2):192–199CrossRef Engledow A, Chan S, Forbes A et al (2010) The management of enterocutaneous fistula in a regional unit in the United kingdom: a prospective study. Dis Colon Rectum 53(2):192–199CrossRef
4.
Zurück zum Zitat Ravindran P, Ansari N, Young CJ et al (2014) Definitive surgical closure of enterocutaneous fistula: outcome and factors predictive of increased postoperative morbidity. Colorectal Dis 16(3):209–218CrossRef Ravindran P, Ansari N, Young CJ et al (2014) Definitive surgical closure of enterocutaneous fistula: outcome and factors predictive of increased postoperative morbidity. Colorectal Dis 16(3):209–218CrossRef
5.
Zurück zum Zitat Owen RM, Love TP, Perez SD et al (2013) Definitive surgical treatment of enterocutaneous fistula. JAMA Surg 148(2):118CrossRef Owen RM, Love TP, Perez SD et al (2013) Definitive surgical treatment of enterocutaneous fistula. JAMA Surg 148(2):118CrossRef
6.
Zurück zum Zitat Atema JJ, Mirck B, Van Arum I et al (2016) Outcome of acute intestinal failure. Br J Surg 103(6):701–708CrossRef Atema JJ, Mirck B, Van Arum I et al (2016) Outcome of acute intestinal failure. Br J Surg 103(6):701–708CrossRef
7.
Zurück zum Zitat Hodgkinson JD, Maeda Y, Leo CA et al (2017) Complex abdominal wall reconstruction in the setting of active infection and contamination: a systematic review of hernia and fistula recurrence rates. Colorectal Dis 19:319–330CrossRef Hodgkinson JD, Maeda Y, Leo CA et al (2017) Complex abdominal wall reconstruction in the setting of active infection and contamination: a systematic review of hernia and fistula recurrence rates. Colorectal Dis 19:319–330CrossRef
8.
Zurück zum Zitat Atema JJ, de Vries FEE, Boermeester MA (2016) Systematic review and meta-analysis of the repair of potentially contaminated and contaminated abdominal wall defects. Am J Surg 212(5):982–995.e1CrossRef Atema JJ, de Vries FEE, Boermeester MA (2016) Systematic review and meta-analysis of the repair of potentially contaminated and contaminated abdominal wall defects. Am J Surg 212(5):982–995.e1CrossRef
9.
Zurück zum Zitat Connolly PT, Teubner A, Lees NP et al (2008) Outcome of reconstructive surgery for intestinal fistula in the open abdomen. Ann Surg 247(3):440–444CrossRef Connolly PT, Teubner A, Lees NP et al (2008) Outcome of reconstructive surgery for intestinal fistula in the open abdomen. Ann Surg 247(3):440–444CrossRef
10.
Zurück zum Zitat Shah B, Tiwari M, Goede M et al (2011) Not all biologics are equal! Hernia 15:165–171CrossRef Shah B, Tiwari M, Goede M et al (2011) Not all biologics are equal! Hernia 15:165–171CrossRef
11.
Zurück zum Zitat Krpata D, Stein S, Eston M et al (2013) Outcomes of simultaneous large complex abdominal wall reconstruction and enterocutaneous fistula takedown. Am J Surg 205:354–359CrossRef Krpata D, Stein S, Eston M et al (2013) Outcomes of simultaneous large complex abdominal wall reconstruction and enterocutaneous fistula takedown. Am J Surg 205:354–359CrossRef
12.
Zurück zum Zitat Sbitany H, Kwon E, Chern H et al (2015) Outcomes analysis of biologic mesh use for abdominal wall reconstruction in clean-contaminated and contaminated ventral hernia repair. Ann Plast Surg 75:201–204CrossRef Sbitany H, Kwon E, Chern H et al (2015) Outcomes analysis of biologic mesh use for abdominal wall reconstruction in clean-contaminated and contaminated ventral hernia repair. Ann Plast Surg 75:201–204CrossRef
13.
Zurück zum Zitat Vaizey CJ, Maeda Y, Barbosa E et al (2016) European Society of Coloproctology consensus on the surgical management of intestinal failure in adults. Colorectal Dis 18(6):535–548CrossRef Vaizey CJ, Maeda Y, Barbosa E et al (2016) European Society of Coloproctology consensus on the surgical management of intestinal failure in adults. Colorectal Dis 18(6):535–548CrossRef
14.
Zurück zum Zitat Parker M, Goldberg RF, Dinkins MM et al (2011) Pilot study on objective measurement of abdominal wall strength in patients with ventral incisional hernia. Surg Endosc Other Interv Tech 25(11):3503–3508CrossRef Parker M, Goldberg RF, Dinkins MM et al (2011) Pilot study on objective measurement of abdominal wall strength in patients with ventral incisional hernia. Surg Endosc Other Interv Tech 25(11):3503–3508CrossRef
15.
Zurück zum Zitat Atema J, de Vries F, Boermeester MA (2016) Systematic review and meta-analysis of the repair of potentially contaminated and contaminated abdominal wall defects. Am J Surg 212:982–995CrossRef Atema J, de Vries F, Boermeester MA (2016) Systematic review and meta-analysis of the repair of potentially contaminated and contaminated abdominal wall defects. Am J Surg 212:982–995CrossRef
16.
Zurück zum Zitat Itani KMF, Rosen M, Vargo D et al (2012) Prospective study of single-stage repair of contaminated hernias using a biologic porcine tissue matrix: the RICH study. Surgery (United States) 152(3):498–505 Itani KMF, Rosen M, Vargo D et al (2012) Prospective study of single-stage repair of contaminated hernias using a biologic porcine tissue matrix: the RICH study. Surgery (United States) 152(3):498–505
17.
Zurück zum Zitat Slater N, Bokkerink W, Konijn V et al (2015) Safety and durability of one-stage repair of abdominal wall defects with enteric fistulas. Ann Surg 261:553–557CrossRef Slater N, Bokkerink W, Konijn V et al (2015) Safety and durability of one-stage repair of abdominal wall defects with enteric fistulas. Ann Surg 261:553–557CrossRef
18.
Zurück zum Zitat Richmond B, Ubert A, Judhan R et al (2014) Component separation with porcine acellular dermal reinforcement is superior to traditional bridged mesh repairs in the open repair of significant midline ventral hernia defects. Am Surg. 80(8):725–731PubMedPubMedCentral Richmond B, Ubert A, Judhan R et al (2014) Component separation with porcine acellular dermal reinforcement is superior to traditional bridged mesh repairs in the open repair of significant midline ventral hernia defects. Am Surg. 80(8):725–731PubMedPubMedCentral
19.
Zurück zum Zitat Holihan JL, Askenasy EP, Greenberg JA et al (2016) Component separation vs. bridged repair for large ventral hernias: a multi-institutional risk-adjusted comparison, systematic review, and meta-analysis. Surg Infect (Larchmt) 17(1):17–26CrossRef Holihan JL, Askenasy EP, Greenberg JA et al (2016) Component separation vs. bridged repair for large ventral hernias: a multi-institutional risk-adjusted comparison, systematic review, and meta-analysis. Surg Infect (Larchmt) 17(1):17–26CrossRef
20.
Zurück zum Zitat Giordano S, Garvey PB, Baumann DP et al (2017) Primary fascial closure with biologic mesh reinforcement results in lesser complication and recurrence rates than bridged biologic mesh repair for abdominal wall reconstruction: a propensity score analysis. Surgery 161(2):499–508CrossRef Giordano S, Garvey PB, Baumann DP et al (2017) Primary fascial closure with biologic mesh reinforcement results in lesser complication and recurrence rates than bridged biologic mesh repair for abdominal wall reconstruction: a propensity score analysis. Surgery 161(2):499–508CrossRef
21.
Zurück zum Zitat Köckerling F, Alam NN, Antoniou SA et al (2018) What is the evidence for the use of biologic or biosynthetic meshes in abdominal wall reconstruction? Hernia 22(2):249–269CrossRef Köckerling F, Alam NN, Antoniou SA et al (2018) What is the evidence for the use of biologic or biosynthetic meshes in abdominal wall reconstruction? Hernia 22(2):249–269CrossRef
22.
Zurück zum Zitat Iacco A, Adeyemo A, Riggs T et al (2014) Single institutional experience using biological mesh for abdominal wall reconstruction. Am J Surg 208(3):480–484CrossRef Iacco A, Adeyemo A, Riggs T et al (2014) Single institutional experience using biological mesh for abdominal wall reconstruction. Am J Surg 208(3):480–484CrossRef
23.
Zurück zum Zitat Basta MN, Fischer JP, Kovach SJ (2015) Assessing complications and cost-utilization in ventral hernia repair utilizing biologic mesh in a bridged underlay technique. Am J Surg 209(4):695–702CrossRef Basta MN, Fischer JP, Kovach SJ (2015) Assessing complications and cost-utilization in ventral hernia repair utilizing biologic mesh in a bridged underlay technique. Am J Surg 209(4):695–702CrossRef
24.
Zurück zum Zitat Sneiders D, Jairam AP, de Smet GHJ et al (2020) Incisional hernia cannot be diagnosed by a patient-reported diagnostic questionnaire. J Surg Res. 245:656–662CrossRef Sneiders D, Jairam AP, de Smet GHJ et al (2020) Incisional hernia cannot be diagnosed by a patient-reported diagnostic questionnaire. J Surg Res. 245:656–662CrossRef
Metadaten
Titel
Long-term outcomes after contaminated complex abdominal wall reconstruction
verfasst von
F. E. E. de Vries
J. D. Hodgkinson
J. J. M. Claessen
O. van Ruler
C. A. Leo
Y. Maeda
O. Lapid
M. C. Obdeijn
P. J. Tanis
W. A. Bemelman
J. Constantinides
G. B. Hanna
J. Warusavitarne
C. Vaizey
M. A. Boermeester
Publikationsdatum
20.02.2020
Verlag
Springer Paris
Erschienen in
Hernia / Ausgabe 3/2020
Print ISSN: 1265-4906
Elektronische ISSN: 1248-9204
DOI
https://doi.org/10.1007/s10029-020-02124-7

Weitere Artikel der Ausgabe 3/2020

Hernia 3/2020 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.